Use of the Chromogenic Factor X Assay to Predict the International Normalized Ratio in Patients Transitioning from Argatroban to Warfarin
Authors:
- Paul A. ArpinoPAPaul A. Arpino
- Elizabeth M. Van CottECElizabeth M. Van Cott
- 1 February 2005
- journal article
- clinical trial
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 25 (2) , 157-164
Abstract
Study Objective. To determine the clinical utility of the chromogenic factor X level for conversion from argatroban to warfarin in hospitalized patients. Design. Prospective observational study. Patients. Sixty‐two hospitalized patients with indications for anticoagulation in whom the chromogenic factor X assay was used for conversion from argatroban to warfarin. Setting. University‐affiliated hospital. Intervention. From December 2003–May 2004, data for all patients in whom the chromogenic factor X assay was used for conversion from argatroban to warfarin were screened for inclusion. When the chromogenic factor X level was satisfactory, the clinician discontinued the argatroban and a confirmatory international normalized ratio (INR) was obtained. Measurements and Main Results. To determine the ability of the chromogenic factor X level to predict the INR free of argatroban influence, we calculated the sensitivity and specificity by using a cutoff chromogenic factor X level of 45% or less, or greater than 45%, which corresponded to an INR of 2 or greater, or less than 2, respectively. We constructed a receiver operating characteristic curve to illustrate various cutoff levels of chromogenic factor X. Of 146 patients screened, 62 had data that met criteria for analysis. An average of 6 ± 3 doses of warfarin were administered before the confirmatory coagulation studies were obtained. The average time from the chromogenic factor X measurement to obtainment of confirmatory coagulation studies was 9 ± 4 hours. Use of a chromogenic factor X level of 45% or less to predict an INR of 2 or greater absent of argatroban influence had a sensitivity of 93%, a specificity of 78%, and an accuracy of 89%. The area under the receiver operating characteristic curve was 0.91 (95% confidence interval 0.81–0.99, pConclusion. The chromogenic factor X level is an accurate alternative when converting hospitalized patients from argatroban to warfarin. A chromogenic factor X level of 45% or less is a reliable predictor that the INR will be therapeutic when argatroban therapy is discontinued.Keywords
This publication has 12 references indexed in Scilit:
- Effect of Direct Thrombin Inhibitors, Bivalirudin, Lepirudin, and Argatroban, on Prothrombin Time and INR ValuesAmerican Journal of Clinical Pathology, 2004
- Heparin-induced thrombocytopenia and cardiac surgeryThe Annals of Thoracic Surgery, 2003
- Recombinant Hirudin in Clinical PracticeCirculation, 2001
- Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic RangeChest, 2001
- Managing Oral Anticoagulant TherapyChest, 2001
- Interpreting the International Normalized Ratio (INR) in Individuals Receiving Argatroban and WarfarinThrombosis and Haemostasis, 2001
- Heparin-Induced ThrombocytopeniaDrug Safety, 1997
- Monitoring Warfarin Therapy in Patients with Lupus AnticoagulantsAnnals of Internal Medicine, 1997
- A 14-year study of heparin-induced thrombocytopeniaThe American Journal of Medicine, 1996
- Multicenter evaluation of a new chromogenic factor X assay in plasma of patients on oral anticoagulantsThrombosis Research, 1980